Infliximab: 12 years of experience
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are immune-mediated conditions that share an inflammatory mechanism fuelled by excessive cytokines, particularly TNF. Control of inflammation and rapid suppression of cytokines are important in treating these diseas...
Main Authors: | Smolen, Josef S, Emery, Paul |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123963/ |
Similar Items
-
The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
by: Han, Chenglong, et al.
Published: (2007) -
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
by: Vande Casteele, Niels, et al.
Published: (2015) -
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
by: Ducourau, Emilie, et al.
Published: (2011) -
Infliximab for the treatment of plaque psoriasis
by: Gall, Jennifer S, et al.
Published: (2008) -
Infliximab in ulcerative colitis
by: Levin, Avi, et al.
Published: (2008)